Literature DB >> 29557759

Cannabis and psychosis: what do we know and what should we do?

Marco Colizzi1, Robin Murray2.   

Abstract

It is now incontrovertible that heavy use of cannabis increases the risk of psychosis. There is a dose-response relationship and high potency preparations and synthetic cannabinoids carry the greatest risk. It would be wise to await the outcome of the different models of legalisation that are being introduced in North America, before deciding whether or not to follow suit. Declaration of interest None.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29557759     DOI： 10.1192/bjp.2018.1

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  10 in total

1.  Management of Adolescent Substance Use Disorders, With an Emphasis on Cannabis Use Disorders.

Authors:  Jeffery N Wilkins
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

2.  Barriers to the wider adoption of medicinal Cannabis.

Authors:  Stephen Ph Alexander
Journal:  Br J Pain       Date:  2020-05-29

3.  Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity.

Authors:  Lisa-Marie Greenwood; Samantha J Broyd; Hendrika H van Hell; Juanita Todd; Alison Jones; Robin M Murray; Rodney J Croft; Patricia T Michie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2021-11-01       Impact factor: 4.530

4.  The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme.

Authors:  Charlotte Gayer-Anderson; Hannah E Jongsma; Marta Di Forti; Diego Quattrone; Eva Velthorst; Lieuwe de Haan; Jean-Paul Selten; Andrei Szöke; Pierre-Michel Llorca; Andrea Tortelli; Celso Arango; Julio Bobes; Miguel Bernardo; Julio Sanjuán; José Luis Santos; Manuel Arrojo; Mara Parellada; Ilaria Tarricone; Domenico Berardi; Mirella Ruggeri; Antonio Lasalvia; Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Paulo Rossi Menezes; Cristina Marta Del-Ben; Bart P Rutten; Jim van Os; Peter B Jones; Robin M Murray; James B Kirkbride; Craig Morgan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-01-23       Impact factor: 4.328

5.  Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans.

Authors:  Marco Colizzi; Nathalie Weltens; Philip McGuire; Lukas Van Oudenhove; Sagnik Bhattacharyya
Journal:  Brain Sci       Date:  2019-04-25

Review 6.  Cannabis and Psychosis: Are We any Closer to Understanding the Relationship?

Authors:  Ian Hamilton; Mark Monaghan
Journal:  Curr Psychiatry Rep       Date:  2019-06-04       Impact factor: 5.285

7.  Acute Psychosis Following 1,1-Difluoroethane Inhalation.

Authors:  Clara B Novotny; Sarah Irvin; Eduardo D Espiridion
Journal:  Cureus       Date:  2019-09-04

Review 8.  Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.

Authors:  Marco Colizzi; Mirella Ruggeri; Sagnik Bhattacharyya
Journal:  Front Psychol       Date:  2020-05-14

Review 9.  Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?

Authors:  Marco Colizzi; Antonio Lasalvia; Mirella Ruggeri
Journal:  Int J Ment Health Syst       Date:  2020-03-24

Review 10.  The Construct of Medical and Non-Medical Marijuana-Critical Review.

Authors:  Andrzej Silczuk; Daria Smułek; Marcin Kołodziej; Julia Gujska
Journal:  Int J Environ Res Public Health       Date:  2022-02-27       Impact factor: 3.390
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.